Agios Pharmaceuticals (FRA:8AP) ROCE %: -37.85% (As of Mar. 2026)

What is Agios Pharmaceuticals ROCE %?

Agios Pharmaceuticals FRA:8AP +3.23% 44 ROCE % is -37.85% as of Mar. 2026. GuruFocus rates FRA:8AP with a GF Score™ of 44/100 and a GF Value™ of €70.71 (Possible Value Trap). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Agios Pharmaceuticals's annualized ROCE % for the quarter that ended in Mar. 2026 was -37.85%.

Agios Pharmaceuticals (FRA:8AP) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Agios Pharmaceuticals ROCE % Related Terms

Agios Pharmaceuticals ROCE % Historical Data

* Premium members only.

The historical data trend for Agios Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Agios Pharmaceuticals ROCE % Chart

Agios Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

-36.34

-31.53

-37.65

-35.23

-31.64

Agios Pharmaceuticals Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															-27.20	-33.83	-34.17	-38.55	-37.85

44GF Score

Agios Pharmaceuticals Inc FRA:8AP

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Agios Pharmaceuticals ROCE % Calculation

Agios Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	-403.201	/	( ( (1588.355 - 77.504)	+	(1107.83 - 70.204) )	/ 2 )
	=	-403.201	/	( (1510.851	+	1037.626)	/ 2 )
	=	-403.201	/	1274.2385
	=	-31.64 %

Agios Pharmaceuticals's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	-380.688	/	( ( (1107.83 - 70.204)	+	(1025.016 - 50.901) )	/ 2 )
	=	-380.688	/	( ( 1037.626	+	974.115 )	/ 2 )
	=	-380.688	/	1005.8705
	=	-37.85 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -37.85% mean?

Agios Pharmaceuticals (FRA:8AP) has a ROCE % of -37.85% as of Mar. 2026.

Is Agios Pharmaceuticals' ROCE % too high?

Agios Pharmaceuticals' current ROCE % is -37.85%. Overall, Agios Pharmaceuticals has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does Agios Pharmaceuticals' ROCE % compare to CAPR and SNDX?

Agios Pharmaceuticals' ROCE % of -37.85% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Biotechnology company?

A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. Agios Pharmaceuticals's current ROCE % is -37.85%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Agios Pharmaceuticals stock overvalued right now?

Based on GuruFocus' analysis, Agios Pharmaceuticals (FRA:8AP) is currently considered Possible Value Trap. The stock's GF Value™ is €70.71, compared to a current price of €32.00 — trading 54.7% below its estimated fair value. The current ROCE % is -37.85%. Agios Pharmaceuticals' overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Agios Pharmaceuticals (FRA:8AP), the current ROCE % is -37.85% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Agios Pharmaceuticals (FRA:8AP) Overvalued in 2026?

Based on GuruFocus' analysis, Agios Pharmaceuticals stock appears to be undervalued. The current stock price of €32.00 is trading 54.7% below its estimated GF Value™ of €70.71. GuruFocus considers Agios Pharmaceuticals to be Possible Value Trap.

Key valuation signals for FRA:8AP:

ROCE %: -37.85%
GF Value™: €70.71 vs. price of €32.00 (54.7% below fair value)
GF Score™: 44/100 with 4 warning signs

No single metric tells the full story. See the FRA:8AP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Agios Pharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies CAPR SNDX SLS VCEL PVLA QURE NVAX TSHA GENB ATAI VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges AGIO:USA 0HB0:UK 8AP:Germany

Address 88 Sidney Street, Cambridge, MA, USA, 02139

Website https://www.agios.com

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

44GF Score

Get the complete analysis for FRA:8AP

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€32.00

Price

€70.71

GF Value

View FRA:8AP Analysis

See ROCE % data for all stocks →